[2] Li Y, Abudureheiyimu N, Mo H, et al. In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Front Oncol....
[16] Ana Christina Garrido-Castro et al., SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. JCO 42, LBA1004-LBA1004(2024). 精彩资讯等你来 审核专家:范蕾教授 责任...
[14]REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+ HER2-negative breast cancer: results from TEXT and SOFT[J]. J Clin Oncol, 2018, 36(suppl 15): 503-503. [15]LAMBERTINI ...
20、Binghe Xu,et al.Sacituzumab govitecan(SG)vs treatment of physician’s choice(TPC)in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative(HR+/HER2–)metastatic breast cancer(mBC):Results from the ...
[5]Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004;351(27):2817-2826. [6]Fasching, Peter A et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positiv...
日前,复旦大学附属肿瘤医院邵志敏教授团队在 Nature Genetics 发表研究报告「Molecular classification of hormone receptor-positive HER2-negative breast cancer」,公布了 HR+/HER2-乳腺癌的复旦分型。通过多组学分析,将 HR+/HER2-乳腺癌进一步细分为 4 种亚型。这 4 种亚型在生物学行为、临床特征上存在一定差异,相应...
美国真实世界研究揭示HR低阳性、HR中/高阳性、HR阴性HER2阳性MBC的不同特征。在HER2阳性转移性乳腺癌（MBC）患者中，HR阳性与HR阴性肿瘤患者的治疗模式和临床结局存在差异。根据ASCO/CAP指南[1]，区分HR阳性和HR阴性肿瘤的免疫组织化学检测的现有标准阈值为≥1%，HR低阳性（1%-9%肿瘤细胞HR染色阳性）乳腺癌与传统的...
HJ, Noh WC, Lee ES, Jung YS, Kim LS, Han W, Nam SJ, Gong G-, Kim HJ, Ahn SH. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res...
参考来源:‘Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer’,新闻稿。AstraZeneca;2024年4月2日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。...
一、HER2+/HER2低表达乳腺癌 Enhertu显著延长生存期 HER2低表达定义为免疫组织化学(IHC)评分为1+或IHC 2+且原位杂交(ISH)评分为阴性(IHC 1+或IHC 2+/ISH-),多发生在HR阳性和HR阴性肿瘤中。目前HER2低表达患者不符合HER2靶向治疗的条件,化疗是主要的治疗手段。